151 related articles for article (PubMed ID: 38483130)
21. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.
Vogrig A; Muñiz-Castrillo S; Farina A; Honnorat J; Joubert B
J Neurol; 2022 Mar; 269(3):1701-1714. PubMed ID: 34708250
[TBL] [Abstract][Full Text] [Related]
22. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
24. [Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis].
Yamamoto T; Tsuji S
Brain Nerve; 2010 Aug; 62(8):838-51. PubMed ID: 20714032
[TBL] [Abstract][Full Text] [Related]
25. Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
Sechi E; Zekeridou A
J Thorac Oncol; 2021 Mar; 16(3):381-394. PubMed ID: 33188910
[TBL] [Abstract][Full Text] [Related]
26. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review.
Marini A; Bernardini A; Gigli GL; Valente M; Muñiz-Castrillo S; Honnorat J; Vogrig A
Neurology; 2021 Apr; 96(16):754-766. PubMed ID: 33653902
[TBL] [Abstract][Full Text] [Related]
27. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
28. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
29. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
Seki M; Kitano S; Suzuki S
Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
[TBL] [Abstract][Full Text] [Related]
30. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
31. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF
JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189
[TBL] [Abstract][Full Text] [Related]
32. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
33. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
[TBL] [Abstract][Full Text] [Related]
34. Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer.
Melia A; Fockens E; Sfumato P; Zemmour C; Madroszyk A; Lafforgue P; Pham T
Joint Bone Spine; 2023 Jan; 90(1):105457. PubMed ID: 36116771
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
36. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
Zhong H; Zhou J; Xu D; Zeng X
Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
[TBL] [Abstract][Full Text] [Related]
37. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
38. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review.
Zammit F; Seront E
Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675461
[TBL] [Abstract][Full Text] [Related]
39. Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review.
Dinoto A; Mantovani E; Ferrari S; Mariotto S; Tamburin S
Eur J Neurol; 2023 Mar; 30(3):774-781. PubMed ID: 36325694
[TBL] [Abstract][Full Text] [Related]
40. Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors.
Haraguchi M; Nakao Y; Narita S; Matsumoto K; Fukushima M; Sasaki R; Honda T; Miuma S; Miyaaki H; Nakao K
Cancer Med; 2023 May; 12(9):10636-10646. PubMed ID: 36934436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
